PropThink: Vertex Earnings Demonstrate Incivek’s Short-Lived Stardom

[ACN Newswire] – By Jake KingHepatitis C drug developers have been swiftly moving towards interferon-free, oral regimens, and while Vertex’s (NASDAQ:VRTX) Incivek was briefly the lead treatment in the field, it may soon … more

View todays social media effects on GILD

View the latest stocks trending across Twitter. Click to view dashboard